ARCA Biopharma Inc (ABIO)

2.100 0.000 (0.00%)
Closed USD Disclaimer
2.020 -0.080 (-3.810%)

ARCA Biopharma Inc Company Profile

Equity Type
ARCA biopharma, Inc. is a clinical stage biopharmaceutical company engaged in the development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF), in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that the Company is developing for the treatment of AF in patients with heart failure. The Company's Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The rNAPc2 is in a phase IIb clinical trial as a potential treatment for patients hospitalized with COVID-19.
Contact Information
Westminster,80021 United States
720 940 2200
Top Executives
Robert E. Conway 67 2013 Independent Chairman of the Board
Raymond L. Woosley 75 2013 Independent Director
Anders D. Hove 55 2017 Independent Director
Daniel J. Mitchell 64 2014 Independent Director
Michael R. Bristow 76 2004 Co-Founder, President, CEO & Director
Linda S. Grais 65 2007 Independent Director
Jacob Ma-Weaver 0 2022 Director
James Flynn 42 2022 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.